DEG analysis of CD14+ monocytes showed that MG patients express high levels of the inflammatory markers S100A4, S100A8, S100A9, S100A10, and S100A12. We found most distinguishing pathway changes between MG patients compared to HCs were inflammatory-relevant pathways, including MAPK family signaling, TNF signaling, TLR4, interferon, and interleukin signaling (Fig. 5d). This evidence concerns the gene CD14 and myasthenia gravis.